The purpose of the study is to assess the safety and ability of TAK-583 to relieve pain in subjects with PHN, compared with placebo.

Official Title

A Phase 2, Double Blind, Placebo Controlled, Dose-Ranging Study in Subjects With Postherpetic Neuralgia (PHN) to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Four Doses of TAK-583, Compared With Placebo.


Neuralgia, Postherpetic

Study Type


Study Design

Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study

Further Details

Primary Outcome Measures:

  • Change from baseline in average daily pain intensity score.

PHN can be defined as neuropathic pain which is still present 3 months following healing of the Herpes Zoster rash. Subjects who fulfill this definition of PHN will be eligible for entry into the study. All eligible subjects will enter a baseline phase (7 days) of the study; during this time subjects will record a daily pain score and a daily sleep interference score. Following the baseline phase, eligible subjects will be randomized to receive either TAK-583 or placebo. Subjects will receive study drug for 8 weeks, including 4 return visits to the clinic for assessments. After treatment, subjects will enter a 7-day follow up phase after which the subjects will return for their last visit.

Study Start

October 2006

Eligibility & Criteria

Ages Eligible for Study: 50 Years and above
Genders Eligible for Study: Both

Inclusion Criteria:

  • Male and female subjects with PHN whose pain has been present for >3 months following healing of the herpes zoster rash.
  • Subjects aged 50 years and above.
  • The female subject is not of childbearing potential (eg, sterilized, postmenopausal).

Exclusion Criteria:

  • Subjects who have undergone neurolytic or neurosurgical therapy for PHN.
  • Subjects who are immunocompromized or have clinically significant haematological abnormalities.
  • Subjects having other severe pain which may impair the self assessment of the pain due to PHN.
  • Subjects who have skin conditions in the affected dermatome that could alter sensation.

Total Enrolment


Contact Details

Samantha J Good, PhD +44 207759 5000 Ext. 5075
Jennifer Gillard, BSc +44 207759 5000 Ext. 5058

New South Wales
Sydney, New South Wales, Australia; Recruiting
Maroochydore, Queensland, Australia; Recruiting
Kipparing, Queensland, Australia; Recruiting
Box Hill, Victoria, Australia; Recruiting
Fitzroy, Victoria, Australia; Recruiting
Carlton, Victoria, Australia; Recruiting
Western Australia
Perth, Western Australia, Australia; Recruiting

All content and media on the HealthEngine Blog is created and published online for informational purposes only. It is not intended to be a substitute for professional medical advice and should not be relied on as health or personal advice. Always seek the guidance of your doctor or other qualified health professional with any questions you may have regarding your health or a medical condition. Never disregard the advice of a medical professional, or delay in seeking it because of something you have read on this Website. If you think you may have a medical emergency, call your doctor, go to the nearest hospital emergency department, or call the emergency services immediately.